Search

Researchers can apply for up to US$50,000 in credits per scientific project. The expanded AI for Science programme accepts any researcher and extends beyond its initial biological-science focus to other fields. Biology and chemistry access

MicrobiotiX reported completion of the sentinel cohort in its Phase 1 MP101 trial for Pseudomonas aeruginosa pneumonia. The initial 72-hour assessment raised no safety concern that prevented continuation, and Cohort 1 enrollment was proceed

Bignaud, Lamy-Besnier, Koszul, Debarbieux, Marbouty and colleagues followed the 3D organization of the virulent phage PAK_P3 genome during infection of Pseudomonas aeruginosa. The phage genome rapidly decondenses into a specific 3D organiza

Pauliina Lajunen joined PrecisionPhage as Chief Business Officer in August 2026. PrecisionPhage

Rebekah Dedrick on phage therapy for cystic fibrosis.

An atlas maps 8,484 interactions between 84 phages and 101 clinical Klebsiella strains, alongside GenoPHI. A Nature Microbiology study describes the genome-only model across 115,037 interactions, with experimental validation of 1,240 E. col

EMBL Heidelberg researchers report in Nature that the kinase of phage T7 (T7K) causes almost every bacterial protein to be phosphorylated, at least in part of its pool, within minutes of infection, preferentially targeting DNA-binding prote

Stanford University's Department of Microbiology & Immunology seeks a tenure-track Assistant Professor (University Tenure Line) whose research addresses fundamental and emerging questions across microbiology and/or immunology; the departmen

Armata said it was finalizing activities for a pivotal Phase 3 superiority study of AP-SA02 in complicated Staphylococcus aureus bacteremia, anticipated to start in the second half of 2026. Armata Pharmaceuticals

A peer-reviewed expanded-access case report in Clinical Infectious Diseases describes investigational SNIPR001 use in a kidney transplant recipient with progressive multidrug-resistant Escherichia coli malakoplakia, under a single-patient e

On 12 August 2026 the LEO Foundation announced DKK 61.9 million in Research Grants to 16 international projects, including one to Professor Thomas Sicheritz-Pontén (University of Copenhagen); the foundation's grantee record lists his 2026 R

Tuck Seng Wong and Kang Lan Tee (University of Sheffield) write in The Conversation that a study in which AI models designed complete bacteriophage genomes, some producing working viruses in the laboratory, shows safeguards must develop alo

Postdoctoral position at University of Illinois, Hatoum-Aslan Lab in Urbana, Illinois USA The Hatoum-Aslan Lab seeks a creative and energetic postdoctoral associate to work on an exciting ARPA-H funded team science project studying oral mic

Martha Clokie and Andrew Millard (University of Leicester) write in The Conversation that, after Stanford researchers used AI to design a complete ΦX174-based phage genome, the more useful question is whether AI can explain how natural phag

Stanford researchers led by Brian Hie and Samuel King used Evo 2, a generative AI model that writes whole genomes, to design novel bacteriophage genomes starting from ΦX174. They synthesized nearly 300 phages, tested them against E. coli an

Four CEPID B3 researchers represented the center at Viruses of Microbes in Prague, presenting work on Salmonella phage diversity and approaches to expand phage host range against Escherichia coli. CEPID B3

The M. Iashvili Children’s Central Hospital, Georgia’s only tertiary, multidisciplinary pediatric referral hospital, and the George Eliava Institute of Bacteriophages, Microbiology and Virology have signed a memorandum of cooperation. The h

Hebrew University and Hadassah Medical Center are partners in P-PEAKS UTI, a €15 million international project evaluating personalized phage therapy for recurrent E. coli urinary tract infections. The study plans to enrol approximately 220

The sixth Japanese Phage Therapy Research Meeting was held jointly with the Japan Biofilm Society’s 40th meeting at Kyorin University on July 31 and August 1, 2026. Kyorin University, Mitaka campus, new lecture building A, 3rd floor, Tokyo

Uruguayan biotechnology company Kinzbio reports the first application of phage therapy at Uruguay's Banco de Prótesis, treating a 30-year-old patient with a hip prosthesis infection caused by an antibiotic-resistant Stenotrophomonas maltoph